
Institute for Stem Cell Biology Stanford MEDICINE and Regenerative Medicine CAL POLY HUMBOLDT

Background

Skeletal Stem Cells (SSCs) are the progenitors of the skeletal system, giving rise to **bone**, **cartilage**, and stroma.^{1,2} These populations are defined by their functional output both in-vitro and in-vivo, their ability to self-proliferate, as well as their molecular profile (Fig. 1).

Insights into aging and cancer of the skeletal system have revealed fundamental changes to the transcriptomic landscape of SSCs throughout life that govern their ability to function as healthy stem cells.³ Thus, we explore the significance of **alternative splicing** (AS) in the skeletal system.




In humans, >90% of protein-coding genes undergo post-translational AS.⁴ Through rearrangement of functional domains prior to translation, AS allows a single gene to encode a variety of proteins that may function in varying degrees of similarity or differ entirely in their activity. Recent advances in our understanding of human SSCs (hSSCs) and the skeletal niche have demonstrated the need to examine AS as it relates to skeletal development, aging, loss of skeletal regenerative capacity and skewing of hSSCs towards non-skeletogenic lineage fates. Moreover, mounting evidence that the progression of **osteosarcoma** corresponds with aberrations in the AS machinery, producing cellular phenotypes that result in malignant tumors of the bone.

Objectives

In the present study, we aimed to characterize the relationship between AS and maintenance of hSSCs, the skeletal niche, and osteosarcoma by identifying **RNA-binding proteins** (**RBPs**) involved in cell maintenance and differentiation. We evaluate the effect of **inhibiting these proteins** on cell viability and differentiation potential.


Methods

Bones are provided by our partners in Stanford department Surgery. hSSCs are extracted from human Acute Fx bone and acute fracture-driven callus forcally digested (Fig 2A).




Cells are filtered and stained for surface markers (PDPN+; CD164+; CD73+; Lin-; CD146-) and sorted by FACS. hSSCs are lysed and processed for | $\!\!\!\!\mathcal{S}$ ' RNA microarray analysis or plated for in-vitro assays. Osteosarcoma cells U2OS and SAOS2 were obtained from ATCC.

Large-scale RNA-seq data is processed using replicate Multivariate Analysis of Transcript Splicing (**rMATS**) statistical model and its latest software implementation rMATS-turbo to **discover and** quantify alternative splicing.5,6 We developed a computational approach to prioritize RBPs that might orchestrate AS using time series data over a 12-day time-course of **induced osteogenesis** cell О Ш culture (Fig 2B).



Functional impact of alternative splicing on the transcriptomic landscape and fate of multipotent skeletal stem cells and osteosarcoma

M. Gohazrua K. Butler, Thomas H. Ambrosi, Charles K. F. Chan



1. Chan, C. K. F. et al. Identification of the Mouse Skeletal Stem Cell. Cell 175, 43-56.e21 (2018). 3. Ambrosi, T. H. et al. Aged Ambrosi, T. H. et al. Age skeletal stem cells generate an inflammatory degenerative niche. Nature 597, 256–262 (2021). 4. Pan Q., Shai O., Lee L.J., Frey B.J., Blencowe B.J. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet. 40(12), 1413–1415 (2008). 5. Shen S, Park JW, Lu ZX, Lin L, Henry MD, Wu YN, Zhou Q, Xing Y. rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-Seq data. Proc Natl Acad Sci U S A. 111(51), E5593-601 (2014). 6. Phillips JW, Pan Y, Tsai BL, Xie Z, Demirdjian L, Xiao W, Yang HT, Zhang Y, Lin CH, Cheng D, Hu Q, Liu S, Black DL, Witte ON, Xing Y. Pathway-guided analysis identifies Myc-dependent alternative pre-mRNA splicing in aggressive prostate cancers. Proc Natl Acad Sci U S A. 117(10), 5269-5279 (2020).

Discussion

Our gene expression analysis and rMATS modeling demonstrate the prevalence of AS in hSSCs and osteosarcoma. The **importance of AS** in hSSC maintenance and differentiation is demonstrated by a lack of characteristic lineage differentiation of SSCs and by decrease in cell number and viability.

We show osteogenic-related RBP expression increasing during osteogenesis, and knockdown of these RBPs prevents formation bone-forming lineages from SSCs. age-related bone degeneration.

Inhibition of AS may also be a potential treatment of **osteosarcoma** as demonstrated by chondrogenic differentiation assay (Fig. 6). Both U2OS and SAOS2 cell lines showed **inhibited** extracellular matrix formation and diminished cell viability using small-molecule inhibition of AS. These results indicate the potential therapeutic targets for treatment of intractable bone cancers such as osteosarcoma.

The importance of AS in hSSCs is made clear by our study, but more work must be done to further reveal how the transcriptional landscape of hSSCs changes during various cell stages. Critically, **age differences** in the expression of RBPs are observed and may play a larger role in the features of skeletal aging, such as skewed lineage differentiation and limits to hSSC proliferation. Significant **sex differences were not observed** during our studies, but more patient samples must be analyzed to determine whether sexual dimorphisms of the hSSC transcriptional landscape

Future Directions

We aim to further investigate the transcriptional targets of RBPs involved in hSSC differentiation, and to determine whether overexpression of these RBPs may instigate greater hSSC differentiation/proliferation.


We plan for **in-vivo analysis** of RBP expression using rMATS through renal capsule transplantation, and will Plan for in-vivo engraftment of hSSCs onto the mouse kidney capsule for RNA-seq analyassess RNA expression at various time points (Fig.7). sis. hSSCs will be collected and analysed for RNA expression at day 0, 7, and week 8 post-engraftmepoints for evaluation of RBP expression and motif enrichment. Knockdown or overexpression of RBPs in engrafted SSCs may provide insight into the potential to **upregulate bone and cartilage** formation in the mouse renal capsule with translation applications to human autologous therapy.

We plan to investigate the potential therapeutic capacity of AS inhibition in **osteosarcoma** by local versus systemic administration of small molecules in osteosarcoma-engrafted mice. Such results may offer an avenue for treatment of intractable bone diseases and skeletal degeneration due to over-abundance of bone-resorbing cells.

Acknowledgments This work was funded by the California Institute for Regenerative Medicine, Bridges 3.0 program grant #EDUC2-12620 and the National Institute on Aging grant K99-R00AG049958-01A1.

Thank you to Dr. Amy Sprowles, Dr. Jenny Cappuccio, and Dr. Brigitte Blackman for your invaluable guidance and mentorship during this internship.





These results indicate a **potential target** for bone deficiency disorders such as osteoporosis, osteoarthritis, and

